Education
About Us
Working with TipRanks
Follow Us
Alzamend Neuro (ALZN)
NASDAQ:ALZN
ALZN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.64 - $15.06
Previous Close$1.15
Volume144.13K
Average Volume (3M)663.36K
Market Cap
$6.73M
Enterprise ValueN/A
Total Cash (Recent Filing)$3.36M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.16
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.06
Shares Outstanding6,597,507
10 Day Avg. Volume260,544
30 Day Avg. Volume663,361
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$32.00Price Target Upside3037.25% Upside
Rating ConsensusHold
Number of Analyst Covering1
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsAlzamend Neuro announced plans to initiate the first of five planned Phase 2 clinical trials for AL001, which aims to demonstrate improved brain absorption with lower blood levels.
Financial StrategyThe company has taken steps to improve the balance sheet, including a convertible preferred offering for up to $25M and an ATM for up to $6.5M.
Bears Say
Financing OverhangWith the inherent uncertainty of an ongoing financing agreement and its current cash balance, a financing overhang remains.
---
Ownership Overview
2.94% Insiders
0.30% Mutual Funds
0.19% Other Institutional Investors
96.44% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ALZN FAQ
What was Alzamend Neuro’s price range in the past 12 months?
Alzamend Neuro lowest stock price was $0.64 and its highest was $15.06 in the past 12 months.
What is Alzamend Neuro’s market cap?
Alzamend Neuro’s market cap is $6.73M.
When is Alzamend Neuro’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Alzamend Neuro’s earnings last quarter?
Alzamend Neuro released its earnings results on Mar 15, 2022. The company reported -$4.5 earnings per share for the quarter, the consensus estimate of -$4.5 by $0.
Is Alzamend Neuro overvalued?
According to Wall Street analysts Alzamend Neuro’s price is currently Undervalued.
Does Alzamend Neuro pay dividends?
Alzamend Neuro does not currently pay dividends.
What is Alzamend Neuro’s EPS estimate?
Alzamend Neuro’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alzamend Neuro have?
Alzamend Neuro has 6,597,507 shares outstanding.
What happened to Alzamend Neuro’s price movement after its last earnings report?
Alzamend Neuro reported an EPS of -$4.5 in its last earnings report, expectations of -$4.5. Following the earnings report the stock price went down -4.798%.
Which hedge fund is a major shareholder of Alzamend Neuro?
Currently, no hedge funds are holding shares in ALZN
---
Company Description
Alzamend Neuro
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
---
ALZN Stock 12 Month Forecast
Average Price Target
$32.00
▲(3037.25% Upside)
Technical Analysis
Cassava Sciences
―
Anavex Life Sciences
―
Bioxcel Therapeutics
―
Inmune Bio
―
Annovis Bio
―
Best Analysts Covering ALZN
1 Year
1 Year Success Rate
0/11 ratings generated profit
1 Year Average Return
-71.83%
reiterated a buy rating 3 months ago
Copying Edward Woo's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -71.83% per trade.
---